Novartis ($NVS) is looking to distinguish its new med Cosentyx from a bevy of next-gen psoriasis-fighters with additional nods, including one for ankylosing spondylitis. But it's not the only company with that idea. Johnson & Johnson's ($JNJ) Stelara--currently approved for treating plaque psoriasis and psoriatic arthritis--will eventually give the Swiss drugmaker a run for its money in the field, according to research and consulting firm GlobalData. It expects the med to launch for that condition in the U.S. and 5 European countries in the second half of 2020, following up with a rollout in nonradiographic axial spondyloarthritis in the first half of the following year. The ensuing sales haul? Combined axial spondyloarthritis sales of $244.7 million in 2024, it predicts. More from FiercePharmaMarketing